Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Vepoloxamer

A purified form of the non-ionic polyoxypropylene-based copolymer poloxamer 188 comprised of a hydrophobic core with hydrophilic side chains, with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Purpose Vepoloxamer (VEPO), a rheologic agent, repairs damaged cell membranes, thus inhibiting unregulated Ca 2+ entry into… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2019
2019
Background and Purpose- Thrombolytic treatment of acute ischemic stroke with tPA (tissue-type plasminogen activator) is hampered… Expand
2019
2019
Stroke is a leading cause of death and disability worldwide, mainly affecting the elderly. To date, tissue plasminogen activator… Expand
2018
2018
Vepoloxamer is an amphipathic polymer that has shown potent hemorrheologic, cytoprotective, and anti-inflammatory effects in both… Expand
2018
2018
Objective Poloxamer‐188 is a synthetic, organic compound that acts by binding hydrophobic pockets on damaged lipid bilayers in… Expand
  • table I
  • table II
  • table III
  • table IV
  • figure 1
2018
2018
Traumatic brain injury (TBI): Despite improved supportive and rehabilitative care of TBI patients, TBI remains a leading cause of… Expand
  • figure 1
2017
2017
BACKGROUND Use of the plasticiser di(2-ethylhexyl) phthalate (DEHP) in polyvinyl chloride (PVC) blood bags poses a potential… Expand
Review
2016
Review
2016
Sickle Cell Disease (SCD) is an autosomal recessive disorder caused by a single amino acid substitution in the Hemoglobin (Hb… Expand
  • figure 2
  • figure 3
  • figure 1
  • figure 4
  • figure 5
2015
2015
Background: Sickle erythrocyte adhesion and membrane fragility contribute to vaso-occlusion and downstream tissue and organ… Expand
2015
2015
Introduction: Ca2+ overload occurs in heart failure (HF) leading to cardiomyocyte dysfunction and death. Vepoloxamer (VEPO… Expand